Resources – Apterna | Precision Therapies for Liver Disease, Metabolic Syndrome & Obesity

Sharing Science. Building Trust.

Apterna is committed to transparency and collaboration. Our publications, news, and resources reflect our ongoing dedication to advancing RNA medicine responsibly — from early discovery through translational research.

Making Research Accessible, Accurate, and Ethical

As a preclinical biotechnology company, Apterna’s progress depends on collaboration with the wider scientific community. We share our findings through peer-reviewed journals, scientific conferences, and collaborative presentations — ensuring that each dataset we release meets the highest standards of reproducibility and integrity.

Transparency

All data shared externally are peer-reviewed or independently verified.

Ethical Integrity

We publish only after confirming safety, quality, and compliance.

Collaboration

We view open scientific exchange as the foundation of innovation in RNA medicine.

Peer-Reviewed Research and Presentations

Apterna and its collaborators regularly contribute to the growing body of knowledge in RNA therapeutics, liver biology, and targeted delivery systems.

Title

Authors

Publication

Year

Precision RNA Delivery Platforms for Hepatic and CNS Applications

Describes the foundational rationale for organ-targeted RNA therapeutics, including safety and scalability.

Habib N, Rossi J, Doogan D, et al.

Molecular Therapy (Review)

2024

Advances in RNA Delivery Chemistry: A Non-Viral Perspective

Reviews emerging conjugate and aptamer systems for targeted delivery to liver and brain tissues.

Swiderski P, Huber H, Nichols J, et al.

RNA Biology

2023

Translational Pathways for Precision RNA Medicines

Summarises Apterna’s translational strategy and roadmap to IND readiness.

Habib N, Doogan D, Huang K-W

Global RNA Therapeutics Summit

2025 (Poster)

Company Updates and Announcements

Stay informed about Apterna’s milestones, collaborations, and scientific progress as we advance toward clinical translation.

RECOGNITION

Apterna Selected for UK RNA Therapeutics Showcase 2025

Invited to present precision RNA delivery platforms at the UK RNA Therapeutics Innovation Forum, highlighting preclinical progress in liver and CNS applications.

PARTNERSHIP

Collaboration with Leading CRO Announced

Partnership with GLP-certified contract research organisation to complete toxicology and biodistribution studies for lead liver-targeted programme.

INTELLECTUAL PROPERTY

Collaboration with Leading CRO Announced

Partnership with GLP-certified contract research organisation to complete toxicology and biodistribution studies for lead liver-targeted programme.

ADVISORY BOARD

Global Experts Join Advisory Board

Renowned academic and industry leaders join Apterna to support preclinical and translational development strategy.

Sharing Our Progress with the Global Scientific Community

Apterna’s researchers actively participate in scientific conferences focused on RNA delivery, liver disease, and oncology.

EASL

RNA Summit

RNA Leaders

ESGCT

BioTechX

Resources for Partners and Stakeholders

Downloadable non-confidential materials for investors, collaborators, and media partners, regularly updated as programmes advance.

Corporate Overview Deck

Mission, platforms, and development roadmap summary.

Platform Summary

Liver and brain-targeted delivery technologies overview.

Fact Sheet 2025

Key statistics, leadership, and progress snapshot.

Brand & Media Kit

Logos, imagery, and boilerplate text for media use.

Approved Brand Assets and Messaging

Official brand elements, photography, and editorial guidance for journalists, collaborators, and partners.

Contents Include:

Company logos

Light and dark variants

Boilerplate text

≤150 words for press use

Photography

Executive headshots and lab imagery

Style guide

Executive headshots and lab imagery

Stay Updated With Our Progress

Downloadable non-confidential materials for investors, collaborators, and media partners, regularly updated as programmes advance.

Advancing Science Through Collaboration and Transparency

Apterna believes that meaningful innovation in RNA medicine begins with open communication and shared knowledge. Every publication, poster, and press release reflects our commitment to rigorous science and our responsibility to patients who will one day benefit from it.